With effect from December 1st, 2020, Outi started as the EMEA Sales Manager of HyTest.
She has extensive experience in sales, marketing, and business development at various IVD diagnostics companies including Medix Biochemica,
Roche Diagnostics
and bioMérieux. Outi has wide-ranging experience of business cultures in Europe, APAC, and the Middle East.
We hope that having Outi on board will enable us to provide even better support to our customers with regard to their projects.
Read below Outi's short interview:What are your expectations and how do you think that things will change now that you are on board?At the forefront of my mind is the focus on customer experience. I will create a continuous dialogue with the customers and increase the awareness of high-quality antibodies and antigens with proven scientific data. I will listen with sensible ears and try to pick up on all the needs and market insights in order to influence the new product development at HyTest for the benefit of the customers.
I believe in strong teamwork and sharing information.
What do you enjoy most about your work?I have a passion for medicine, science, and new innovations, which are improving global healthcare and life sciences. As a scientifically and technology-oriented person, I enjoy following the latest developments in the diagnostics technologies, applications, and platforms.
In these global pandemic circumstances, we all understand the value, importance, and significance of rapid R&D in order to manufacture high quality antibodies that serve as a crucial component in diagnostics tests.
HyTest has valuable data proven publications, live webinars, and an impressive advisory board as a background for all the scientific work.
International business inspires me, and I enjoy working in a multicultural and -functional teams with interdisciplinary and experienced experts. Together we are HyTest!
What kind of changes do you see coming in the next few years in your work and the diagnosis of diseases? What are likely to be the future trends?An ageing population, an increasing number of genetic disorders and infectious diseases, the need for rapid tests, as well as pandemic infections appearing from time to time that require quick and reliable testing. Individuals are more aware and interested in self-testing and well-being, which leads to the need for preventive diagnostics. Veterinary diagnostic panels will expand. Lifestyle diseases will continue to increase and cardiovascular, metabolic, thyroid and cancer markers will be in demand. AI, algorithms, and big data will be used more in the data-driven healthcare and risk assessments.
What would you say are the main pain points in the current cardiac disease diagnostics?Large patient flow requesting a quick, reliable, and early need of diagnosis in connection with the prioritization of the patients and the ruling out of the healthier individuals. Accuracy, sensitivity, and specificity of the antibodies are also necessary. Preventive diagnostics and early-on diagnostics are needed.
In general, the antibodies are the crucial component in all the tests. By choosing the highest quality antibodies, the IVD manufacturer shortens the time and cost in product development, validation, and the manufacturing stage, and it shortens the time-to-market with the new generation cardiac markers.
